About Tyrosine aminotransferase
Tyrosine aminotransferase (TAT) is a protein
from Homo sapiens identified by UniProt accession
P17735, 454 residues long.
MolForge cross-references it against 0 known binders and
91 disease associations.
Target properties
| Protein name | Tyrosine aminotransferase |
| UniProt accession | P17735 |
| Gene | TAT |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (91)
Diseases linked to this target (Open Targets).
- Tyrosinemia type 2 · score 0.80
- tyrosinemia type II · score 0.77
- Intellectual disability · score 0.46
- Palmoplantar hyperkeratosis · score 0.37
- chronotype measurement · score 0.21
- thyroid gland adenocarcinoma · score 0.18
- genetic disorder · score 0.18
- Hypertyrosinemia · score 0.17
- tyrosine measurement · score 0.17
- sex hormone-binding globulin measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P17735-F1 | alphafold | PREDICTED | 91.74 | — |
Amino-acid sequence (454 residues)
MDPYMIQMSS KGNLPSILDV HVNVGGRSSV PGKMKGRKAR WSVRPSDMAK KTFNPIRAIV DNMKVKPNPN KTMISLSIGD PTVFGNLPTD PEVTQAMKDA LDSGKYNGYA PSIGFLSSRE EIASYYHCPE APLEAKDVIL TSGCSQAIDL CLAVLANPGQ NILVPRPGFS LYKTLAESMG IEVKLYNLLP EKSWEIDLKQ LEYLIDEKTA CLIVNNPSNP CGSVFSKRHL QKILAVAARQ CVPILADEIY GDMVFSDCKY EPLATLSTDV PILSCGGLAK RWLVPGWRLG WILIHDRRDI FGNEIRDGLV KLSQRILGPC TIVQGALKSI LCRTPGEFYH NTLSFLKSNA DLCYGALAAI PGLRPVRPSG AMYLMVGIEM EHFPEFENDV EFTERLVAEQ SVHCLPATCF EYPNFIRVVI TVPEVMMLEA CSRIQEFCEQ HYHCAEGSQE ECDK
Explore Tyrosine aminotransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets